ETERNA THERAPEUTICS INC (ERNA)

US1140822099 - Common Stock

1.71  -0.08 (-4.47%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ETERNA THERAPEUTICS INC

NASDAQ:ERNA (4/29/2024, 9:28:39 AM)

1.71

-0.08 (-4.47%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap9.25M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ERNA Daily chart

Company Profile

Eterna Therapeutics, Inc. engages in the provision of cell engineering therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 9 full-time employees. The firm is focused on developing advanced therapies using messenger ribonucleic acid (RNA) (mRNA) cell engineering technology. The firm has a portfolio of over 100 patents covering mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice and UltraSlice gene-editing proteins, and the ToRNAdo mRNA delivery system, which the Company collectively refers to as its mRNA technology platform. Its mRNA gene-editing technology is designed to delete, insert, and repair deoxyribonucleic acid (DNA) sequences in living cells, which may be useful for correcting disease-causing mutations, making cells resistant to infection and degenerative disease, modulating the expression of immunoregulatory proteins to enable the generation of durable allogeneic cell therapies, and engineering immune cells to fight cancer.

Company Info

ETERNA THERAPEUTICS INC

1035 Cambridge Street, Suite 18A

Cambridge MASSACHUSETTS

P: 12125821199

Employees: 9

Website: https://eternatx.com/

ERNA News

News Image2 months ago - InvestorPlaceISRG Stock Alert: The FDA Is Giving Intuitive Surgical a Big Boost

Intuitive Surgical stock is on the rise Friday as investors in ISRG shares learn about FDA approval for the company's da Vinci 5.

News Image2 months ago - InvestorPlaceERNA Stock Earnings: Eterna Therapeutics Reported Results for Q4 2023

Eterna Therapeutics just reported results for the fourth quarter of 2023.

News Image2 months ago - Eterna TherapeuticsEterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

Eterna Therapeutics (ERNA) Announces the Appointment of Peter Cicala, JD, to its Board of Directors...

News Image4 months ago - Seeking AlphaEterna Therapeutics files to sell 18.2M shares for holders (NASDAQ:ERNA)

Eterna Therapeutics files prospectus for $25M mixed shelf offering, not an offer to sell securities.

News Image4 months ago - Eterna TherapeuticsEterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed...

News Image4 months ago - Seeking AlphaEterna Therapeutics names Sanjeev Luther as CEO (NASDAQ:ERNA)

Eterna Therapeutics names Sanjeev Luther as President and CEO.

ERNA Twits

Here you can normally see the latest stock twits on ERNA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example